Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdCD40L Immunogene Therapy for Advanced Malignant Disease
NCT01455259Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Sep 2011
- Primary completion
- Jan 2016
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of AdCD40L in Malignant Melanoma (MM), solid tumor, sponsored by Uppsala University. Started Sep 2011; status: completed.
02
Drugs
AdCD40L
03
Conditions
Malignant Melanoma (MM)solid tumor
Beyond the preview
Go deeper on NCT01455259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455259.